Own the gold standard ✨ in financial data & analytics

Subscribe for $2
Overview
Profile

Suzhou Highfine Biotech Co Stock

301393.SZ
CNE1000064T6

Price

39.84
Today +/-
+0
Today %
+0 %
P

Suzhou Highfine Biotech Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Suzhou Highfine Biotech Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Suzhou Highfine Biotech Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Suzhou Highfine Biotech Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Suzhou Highfine Biotech Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Suzhou Highfine Biotech Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Suzhou Highfine Biotech Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Suzhou Highfine Biotech Co’s growth potential.

Suzhou Highfine Biotech Co Revenue, EBIT and net profit per share

DateSuzhou Highfine Biotech Co RevenueSuzhou Highfine Biotech Co EBITSuzhou Highfine Biotech Co Net Income
2025e778.71 M undefined264.62 M undefined52.02 M undefined
2024e558.53 M undefined188.87 M undefined37.16 M undefined
2023e396.43 M undefined133.32 M undefined26.38 M undefined
2022447.46 M undefined144.83 M undefined129.37 M undefined
2021369.44 M undefined129.63 M undefined111.4 M undefined
2020282.35 M undefined58.45 M undefined40.4 M undefined

Suzhou Highfine Biotech Co Stock Ratios

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2020202120222023e2024e2025e
282369447396558778
-30.8521.14-11.4140.9139.43
46.4546.3442.95---
131171192000
58129144133188264
20.5734.9632.2133.5933.6933.93
40111129263752
-177.5016.22-79.8442.3140.54
108108108000
------
Details

Keystats

ⓘ

Revenue and Growth

The Suzhou Highfine Biotech Co Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Suzhou Highfine Biotech Co is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Suzhou Highfine Biotech Co provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Suzhou Highfine Biotech Co's financial health and stability.

Assets

Suzhou Highfine Biotech Co's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Suzhou Highfine Biotech Co must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Suzhou Highfine Biotech Co after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Suzhou Highfine Biotech Co's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (k)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
202020212022
000
000
000
-25-46-46
000
000
-25-20-16
8975138
-67-53-81
-73-41-94
-511-12
000
1,000-1,0000
000
0-1-21
---21.00
000
151173226
21.7422.4257.27
000

Suzhou Highfine Biotech Co stock margins

The Suzhou Highfine Biotech Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Suzhou Highfine Biotech Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Suzhou Highfine Biotech Co.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Suzhou Highfine Biotech Co's sales revenue. A higher gross margin percentage indicates that the Suzhou Highfine Biotech Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Suzhou Highfine Biotech Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Suzhou Highfine Biotech Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Suzhou Highfine Biotech Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Suzhou Highfine Biotech Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Suzhou Highfine Biotech Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Suzhou Highfine Biotech Co Margin History

Suzhou Highfine Biotech Co Gross marginSuzhou Highfine Biotech Co Profit marginSuzhou Highfine Biotech Co EBIT marginSuzhou Highfine Biotech Co Profit margin
2025e43.08 %33.98 %6.68 %
2024e43.08 %33.82 %6.65 %
2023e43.08 %33.63 %6.66 %
202243.08 %32.37 %28.91 %
202146.41 %35.09 %30.15 %
202046.75 %20.7 %14.31 %

Suzhou Highfine Biotech Co Stock Sales Revenue, EBIT, Earnings per Share

The Suzhou Highfine Biotech Co earnings per share therefore indicates how much revenue Suzhou Highfine Biotech Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Suzhou Highfine Biotech Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Suzhou Highfine Biotech Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Suzhou Highfine Biotech Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Suzhou Highfine Biotech Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Suzhou Highfine Biotech Co Revenue, EBIT and net profit per share

DateSuzhou Highfine Biotech Co Sales per ShareSuzhou Highfine Biotech Co EBIT per shareSuzhou Highfine Biotech Co Earnings per Share
2025e31.75 undefined0 undefined2.12 undefined
2024e22.77 undefined0 undefined1.52 undefined
2023e16.16 undefined0 undefined1.08 undefined
20224.14 undefined1.34 undefined1.2 undefined
20213.42 undefined1.2 undefined1.03 undefined
20202.61 undefined0.54 undefined0.37 undefined

Suzhou Highfine Biotech Co business model

Suzhou Highfine Biotech Co is one of the most popular companies on Eulerpool.com.

Suzhou Highfine Biotech Co valuation based on historical P/E ratio, EBIT, and P/S ratio.

Suzhou Highfine Biotech Co shares outstanding

The number of shares was Suzhou Highfine Biotech Co in 2023 — This indicates how many shares 108 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Suzhou Highfine Biotech Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Suzhou Highfine Biotech Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Suzhou Highfine Biotech Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Suzhou Highfine Biotech Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Suzhou Highfine Biotech Co Stock Dividend

In 2023, Suzhou Highfine Biotech Co paid a dividend amounting to 0.25 CNY. Dividend means that Suzhou Highfine Biotech Co distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Suzhou Highfine Biotech Co provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Suzhou Highfine Biotech Co’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Suzhou Highfine Biotech Co's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Suzhou Highfine Biotech Co Dividend History

DateSuzhou Highfine Biotech Co Dividend
Suzhou Highfine Biotech Co does not pay out any dividends.
Unfortunately, there are currently no price targets and forecasts available for Suzhou Highfine Biotech Co.

Suzhou Highfine Biotech Co Stock Shareholders

%
Name
Stocks
Change
Date
9.91 % Suzhou Haoqin Venture Capital Partnership LP2,430,0002,430,0009/30/2023
7.93 % Dong (Shengjun)1,944,000012/31/2023
7.93 % Lv (Minjie)1,944,000012/31/2023
7.93 % Lu (Xuegen)1,944,000012/31/2023
6.60 % Xu (Liyan)1,620,0001,620,0009/30/2023
5.04 % China Merchants Fund Management Co. Ltd.1,237,2761,237,2769/30/2023
3.35 % Huatai-PineBridge Fund Management Co., Ltd.822,332822,3329/30/2023
21.14 % Xu (Jie)5,184,000012/31/2023
208.71 % Zhu (Yong)51,192,000012/31/2023
19.81 % Ningbo Haoxin Enterprise Management Consulting P'ship LP4,860,0004,860,0009/30/2023
1
2
3
4
5
...
6

Suzhou Highfine Biotech Co stock: Frequently Asked Questions

What is the P/E ratio of Suzhou Highfine Biotech Co 2024?

The Suzhou Highfine Biotech Co P/E ratio is 115.79.

What is the P/S ratio of Suzhou Highfine Biotech Co 2024?

The Suzhou Highfine Biotech Co P/S ratio is 7.7.

What is the AlleAktien quality score of Suzhou Highfine Biotech Co?

The AlleAktien quality score for Suzhou Highfine Biotech Co is 3/10.

What is the revenue of Suzhou Highfine Biotech Co 2024?

The expected Suzhou Highfine Biotech Co revenue is 558.53 M CNY.

How high is the profit of Suzhou Highfine Biotech Co 2024?

The expected Suzhou Highfine Biotech Co profit is 37.16 M CNY.

What is the business model of Suzhou Highfine Biotech Co

No history available for Suzhou Highfine Biotech Co.

What is the Suzhou Highfine Biotech Co dividend?

Suzhou Highfine Biotech Co pays a dividend of 0 CNY distributed over payouts per year.

How often does Suzhou Highfine Biotech Co pay dividends?

The dividend cannot currently be calculated for Suzhou Highfine Biotech Co or the company does not pay out a dividend.

What is the Suzhou Highfine Biotech Co ISIN?

The ISIN of Suzhou Highfine Biotech Co is CNE1000064T6.

What is the Suzhou Highfine Biotech Co ticker?

The ticker of Suzhou Highfine Biotech Co is 301393.SZ.

How much dividend does Suzhou Highfine Biotech Co pay?

Over the past 12 months, Suzhou Highfine Biotech Co paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Suzhou Highfine Biotech Co is expected to pay a dividend of 0.25 CNY.

What is the dividend yield of Suzhou Highfine Biotech Co?

The current dividend yield of Suzhou Highfine Biotech Co is .

When does Suzhou Highfine Biotech Co pay dividends?

Suzhou Highfine Biotech Co pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Suzhou Highfine Biotech Co?

Suzhou Highfine Biotech Co paid dividends every year for the past 0 years.

What is the dividend of Suzhou Highfine Biotech Co?

For the upcoming 12 months, dividends amounting to 0.25 CNY are expected. This corresponds to a dividend yield of 0.62 %.

In which sector is Suzhou Highfine Biotech Co located?

Suzhou Highfine Biotech Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Suzhou Highfine Biotech Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Suzhou Highfine Biotech Co from 5/23/2024 amounting to 0.25 CNY, you needed to have the stock in your portfolio before the ex-date on 5/23/2024.

When did Suzhou Highfine Biotech Co pay the last dividend?

The last dividend was paid out on 5/23/2024.

What was the dividend of Suzhou Highfine Biotech Co in the year 2023?

In the year 2023, Suzhou Highfine Biotech Co distributed 0 CNY as dividends.

In which currency does Suzhou Highfine Biotech Co pay out the dividend?

The dividends of Suzhou Highfine Biotech Co are distributed in CNY.

Other fundamentals and analyses of Suzhou Highfine Biotech Co in the deep dive.

Our stock analysis for Suzhou Highfine Biotech Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Suzhou Highfine Biotech Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.